UT Khader's 1 Nov drug-price rule gives UAE clinics a 4-point margin check

U T Khader, Karnataka's Health and Family Welfare Minister, said hospitals and laboratories in the Indian state must disclose medicine purchase prices and selling prices from 1 November 2026, a move that gives UAE clinic operators a useful test for pharmacy billing transparency.

The rule reported by Coastal Digest applies to Karnataka, not the UAE. Its relevance for Dubai, Abu Dhabi and the northern emirates is operational. Pharmacy margins sit inside patient bills, insurer approvals and regulator inspections. A disputed medicine charge can become a complaint, a denied claim or a pricing breach.

What Karnataka is changing

Khader said hospitals and laboratories covered by the rule must show the purchase price and the selling price of medicines. The purchase price and maximum retail price must also be reflected in patient bills, according to the 10 October 2026 report.

Patients must know the price at which medicines are purchased and the price at which they are sold.
U T Khader, Karnataka Health and Family Welfare Minister

The announcement followed concern about high medicine costs during treatments such as cancer care. Khader warned that institutions breaching the disclosure requirement would face legal action. The practical shift is simple: the patient sees the margin. The hospital can no longer treat the medicine line as a black box.

For UAE operators, the closest local question is whether pharmacy billing can withstand the same scrutiny. In Dubai, the Dubai Health Authority (DHA) regulates private healthcare facilities. In Abu Dhabi and Al Ain, the regulator is the Department of Health Abu Dhabi (DOH). In Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain, the relevant federal regulator is the Ministry of Health and Prevention (MOHAP), while federal drug registration and pricing functions now sit with the Emirates Drug Establishment (EDE).

The UAE compliance exposure

Dubai already has explicit monetary exposure for pricing failures. Executive Council Resolution No. 49 of 2024 lists a AED 2,000 fine for selling medications or medical products at prices other than those prescribed by MOHAP. It also lists AED 1,000 for failure to comply with prices approved by DHA and AED 5,000 for failure to display healthcare service charges.

Those numbers are modest compared with the commercial issue. A clinic that bills a drug above the approved price risks payer rejection, patient escalation and internal audit findings. For finance teams, the useful control is a monthly sample of high-value medicine lines against the EDE Drug Directory or the current official price list requested through EDE channels.

• COO: confirm that outpatient and inpatient pharmacy bills show medicine name, strength, quantity, unit price and payer share.
• CFO: test the top 20 reimbursed medicines by revenue against approved UAE prices and insurer contract terms.
• CIO: map the pharmacy item master to EDE registration data, internal purchase cost and claims codes.
• Medical director: check that substitutions, oncology drugs and controlled medicines have documented clinical rationale.

Insurers have a direct interest. Claims teams at Daman, Abu Dhabi's Thiqa programme and commercial insurers such as Sukoon can reject or query medicine lines when coding, coverage or price terms do not match the policy. The patient usually sees the dispute last, when co-pay or uncovered medicine charges appear on the invoice.

What UAE clinics should do now

The first action is to separate three figures in the billing workflow: purchase cost, approved selling price and patient charge after insurance. The second is to decide who owns mismatches. In many clinics, procurement owns purchase cost, pharmacy owns dispensing, revenue cycle owns claims and front desk teams handle patient complaints. Medicine-price disputes cut across all four functions.

Dubai operators should review DHA licence conditions, pharmacy standards and price-display obligations before the next inspection cycle. Abu Dhabi providers should check DOH facility requirements and payer contracts, especially where Daman or Thiqa rules affect medicine claims. Northern emirates providers should verify MOHAP facility obligations and EDE medicine registration status before adding new pharmacy items.

There is no UAE rule equivalent to Karnataka's 1 November 2026 disclosure mandate. That is the point. A clinic that can already explain purchase cost, approved price and billed patient amount has less exposure when a regulator, insurer or patient asks for the same audit trail.

Patients and operators checking licensed pharmacy providers can start with the UAE Open Healthcare Directory, which lists 12,394+ licensed healthcare providers across Dubai, Abu Dhabi, Al Ain and the northern emirates.